We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 355

Support growing for request that FDA freeze biosimilar applications
  • Shook Hardy & Bacon LLP
  • USA
  • February 21 2013

The Washington Legal Foundation (WLF), a public interest law and policy center, has filed comments with the U.S. Food and Drug Administration (FDA


FTC conducts workshop on competition and safety in pet meds industry
  • Shook Hardy & Bacon LLP
  • USA
  • October 3 2012

The U.S. Federal Trade Commission (FTC) conducted a day-long workshop, October 2, 2012, “to examine competition and consumer protection issues in the pet medications industry.”


French company prevails in dispute with FDA over drug-classification ruling
  • Shook Hardy & Bacon LLP
  • USA
  • October 3 2012

A federal court in the District of Columbia has determined that the Food and Drug Administration (FDA) erred when it classified a combination drug-device product as primarily a drug, thus subjecting its French manufacturer to more burdensome regulatory requirements


PROLOR Biotech to raise $75 million for clinical trials on growth hormones
  • Shook Hardy & Bacon LLP
  • Israel, USA
  • April 19 2012

In an April 6, 2012, filing with the U.S. Securities and Exchange Commission, Israel-based PROLOR Biotech, Inc. has registered the sale of common stock on the American Stock Exchange in an amount not to exceed $75 million


Biotech secures $5.3 million for immunosuppressant drug research
  • Shook Hardy & Bacon LLP
  • USA
  • April 18 2013

San Francisco-based startup, Nurix, Inc., which reportedly develops T-cellspecific immunosuppressants used to treat autoimmune diseases such as


Takeda acquires access to Envoy’s CNS drug pipeline and bacTRAP technology
  • Shook Hardy & Bacon LLP
  • USA
  • November 15 2012

Takeda America Holdings, Inc. has reportedly acquired Envoy Therapeutics, Inc. in a deal worth $140 million, including an up-front payment and progressdependent milestone payments


Federal Circuit’s patent infringement ruling conflicts with USPTO re-examination on validity
  • Shook Hardy & Bacon LLP
  • USA
  • November 1 2012

The Federal Circuit Court of Appeals has denied a request for an en banc rehearing by a medical-device patent holder which argued that the U.S. Patent and Trademark Office’s (USPTO’s) Board of Patent Appeals had effectively nullified a previous Federal Circuit decision on the validity of its patent


Biotech company settles claims that counsel divulged confidential information
  • Shook Hardy & Bacon LLP
  • USA
  • April 21 2011

A federal court in California has dismissed with prejudice claims that a biotech company filed against its former counsel alleging that the law firm had provided confidential information about the company's patent applications to another client


Joint public meeting to focus on bridging nanotechnology research
  • Shook Hardy & Bacon LLP
  • European Union, USA
  • February 24 2011

The National Nanotechnology Coordination Office has announced that it will spearhead a public meeting to focus on "environmental health and safety questions for nanomaterials and nanotechnology-enabled products" and to "encourage joint US-EU programs of work that would leverage resources."


Company secures $10 million in venture capital financing to improve DNA sequencing technology
  • Shook Hardy & Bacon LLP
  • USA
  • September 22 2011

NABsys, Inc., a Rhode Island-based developer of electronic systems used for sequencing and analyzing single-molecule DNA, has reportedly raised $10 million in new venture capital funding, closing a Series C preferred stock financing round